FLJ39531 inhibitors represent a class of chemical compounds designed and developed primarily for their ability to modulate the activity of the FLJ39531 protein. FLJ39531, also known as C6orf106 or FAM198B, is a relatively less characterized protein whose exact function and role in cellular processes remain under investigation. Researchers have identified this protein as a target for pharmacological intervention due to its association with various biological pathways and cellular functions. As such, FLJ39531 inhibitors are chemical agents designed to interact with this specific protein, either by binding to it directly or by affecting downstream signaling pathways in which FLJ39531 participates.
The development and study of FLJ39531 inhibitors fall within the broader field of drug discovery and chemical biology. Scientists employ a variety of techniques, such as high-throughput screening and structure-based design, to identify and optimize compounds with inhibitory activity against FLJ39531. These inhibitors are essential tools in biological research, enabling scientists to explore the function of FLJ39531 and its implications in cellular processes. While the precise biological significance of FLJ39531 inhibition is still being elucidated, this chemical class plays a vital role in advancing our understanding of the protein's biology and its relevance to human health and disease.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR, used primarily in CML and GISTs. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
tyrosine kinase inhibitor used in non-small cell lung cancer with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor that binds to FKBP12 and inhibits the mTORC1 complex, affecting cell growth and proliferation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor that interferes with the RAS/RAF/MEK/ERK pathway, used in melanoma. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
BRAF inhibitor used in metastatic melanoma with BRAF V600E mutation, inhibiting the MAPK pathway. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor that halts cell cycle progression by blcoking phosphorylation of retinoblastoma protein, used in breast cancer. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that blokcs degradation of ubiquitinated proteins, affecting cell cycle and survival, used in multiple myeloma. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitor studied in the research of ovarian and breast cancers with BRCA1/2 mutations, blocking DNA repair. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multi-kinase inhibitor that targets RAF kinases, VEGFR, and PDGFR, used in renal and hepatocellular carcinoma. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor that promotes apoptosis by blocking the binding of pro-apoptotic proteins, used in chronic lymphocytic leukemia. | ||||||